Hikal Ltd Q3 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/flp4735cw99kdr68sc2pds70.pdf

Key Takeaways


Margin & Input Cost Dynamics

Hiremath: "The margin profile will undergo significant change in the next three to four years compared to where we are today."

Volume & Channel Inventory


Capex Cycle & New Capacity

Hiremath: "We're going to wait for a quarter or so before we finalize our large capex."

CDMO Pipeline & Portfolio Shift

Hiremath: "I think the future is very bright. There are several new projects in both NCE both Pharma and in Crop where we're developing products, which are on patent and under for registration and on the animal side as well. So the future will look very different from the last 10 years..."

ESG & Operational Initiatives


Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA margin targetReach 21–22% on a blended basisNext couple of years
ROCE targetGrow to 16–18%Next couple of years
Pharma volume recoveryVolumes to start coming backQ1–Q2 FY24
Pre-2022 margin recoveryStart moving back to steady-state marginsFrom Q2 FY24 onwards
Panoli plant productionProduction and revenue accrual beginQ1 FY24
New fungicide plant revenueCommissioning complete, revenue accrual startsEarly FY24
Animal Health plant commissioningPlant commissioning completeQ2 FY24
Animal Health commercial supplyCommercial supply starts after 11–12 month validationH2 FY25
Capex peak utilizationPeak optimization of ₹550 Cr capex deployed2–3 years
Gross margin transformationMaterially better blended gross margins vs past4–5 years
FY24 guidanceNo guidance given; waiting and watching macro uncertaintiesRevisit at end of Q4 FY23
Next large capex decisionWait a quarter or so before finalizing~Q4 FY23 / Q1 FY24

Key Metrics

MetricQ3 FY23
Revenue₹540 cr, vs ₹559 cr in Q2 FY23
9M FY23 revenue₹1,478 cr, vs ₹1,440 cr in 9M FY22
EBITDA margin improvement130 bps QoQ improvement vs Q2 FY23
Pharma revenue₹292 cr, vs ₹290 cr in Q2 FY23
Pharma EBIT margin9%, vs 3.6% in Q2 FY23
Pharma 9M FY23 revenue₹806 cr, vs ₹822 cr in 9M FY22
Crop Protection revenue₹248 cr, vs ₹269 cr in Q2 FY23
Crop Protection EBIT margin11%, vs 13% in Q2 FY23
Crop Protection 9M FY23 revenue₹671 cr, vs ₹619 cr in 9M FY22
Crop Protection volume growth~20% YoY
Pharma volume de-growth~17.5% YoY
Total debt₹800 cr, long-term ₹500 cr, short-term ₹300 cr
Cost of funding8.5% long-term, 7% short-term
Capacity utilization80% to 85% across sites
FY23 capex~₹300 cr, ~₹200 cr spent in 9M, ~₹100 cr to be spent in Q4
Asset turns at peak utilization1.4x to 1.5x
Interim dividend30%
Pharma CDMO commercial molecules5 molecules currently in commercial phase
Animal Health plant validation period11 to 12 months from commissioning in Q2 FY24
Solar power agreement12 MW for Maharashtra units, payback under 1 year